Online inquiry

IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5513MR)

This product GTTS-WQ5513MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL17A&IL17F gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002190.3; NM_052872.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 112744
UniProt ID Q16552; Q96PD4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5513MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11379MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-573
GTTS-WQ12480MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NN-8226
GTTS-WQ4671MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-986089
GTTS-WQ5414MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ8616MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HuM195
GTTS-WQ4546MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-936558
GTTS-WQ7533MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GC-182
GTTS-WQ13935MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-2810
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW